To the Editor:
The study by Ying, et al1 of ischemic stroke risk in systemic sclerosis (SSc) reported increased prevalence (15.3 vs 12.2 per thousand in the control cohort) and delineated a series of likely predisposing comorbidities. There is an additional consideration, also amenable to risk adjustment: such events are also characteristic of the effect of antiphospholipid antibodies (aPL)2. The reported prevalence of ischemic events in SSc is characteristic of that noted with aPL, a known association with …
Address correspondence to Dr. B.M. Rothschild, IU Health, 2401 W. University Ave., Muncie, Indiana 47303, USA. E-mail: spondylair{at}gmail.com